Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLARINEX-D 12 HOUR vs ACTAHIST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Relief of symptoms associated with seasonal allergic rhinitis,Relief of symptoms associated with perennial allergic rhinitis,Relief of nasal congestion and sinus pressure
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
1.34 mg (one capsule) orally twice daily.
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Desloratadine: primarily metabolized by CYP3A4 and CYP2D6 to active metabolite 3-hydroxydesloratadine. Pseudoephedrine: partially metabolized in liver by N-demethylation via CYP450 enzymes; largely excreted unchanged in urine.
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Desloratadine: 83-87% (mainly albumin); pseudoephedrine: negligible binding.
92% bound to albumin.
Desloratadine: 49 L (approx. 0.7 L/kg), extensive tissue distribution; pseudoephedrine: 2.6-3.5 L/kg.
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
Desloratadine: 100% (oral); pseudoephedrine: ~100% (oral).
Oral: 68% ± 12% due to first-pass metabolism.
Contraindicated in patients with GFR < 60 m L/min due to pseudoephedrine component.
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
No specific Child-Pugh based adjustments for desloratadine; pseudoephedrine may require caution in severe hepatic impairment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
Not recommended for use in pediatric patients under 12 years of age.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
Use with caution; initiate at lower doses due to increased sensitivity to pseudoephedrine and risk of anticholinergic effects.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
None.
None.
Cardiovascular effects: Use with caution in patients with hypertension, arrhythmias, or ischemic heart disease.,CNS stimulation: May cause insomnia, dizziness, or nervousness.,Urinary retention: Use with caution in patients with prostatic hypertrophy or bladder neck obstruction.,Renal impairment: Reduce dose or avoid in severe renal impairment.,Hepatic impairment: Caution in severe hepatic disease.
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
Hypersensitivity to desloratadine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Concurrent use with MAO inhibitors or within 14 days of stopping MAOI,Narrow-angle glaucoma,Urinary retention,Breastfeeding
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented foods) as pseudoephedrine may potentiate pressor effects. Taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice; it may increase desloratadine levels. Limit caffeine intake as it can add to CNS stimulation.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
Clarinox-D 12 Hour (desloratadine/pseudoephedrine) is classified as FDA Pregnancy Category C. Desloratadine: No adequate studies in pregnant women; animal studies show no teratogenicity at doses 210 times human exposure, but potential for adverse effects is unknown. Pseudoephedrine: Case reports suggest possible association with gastroschisis at first-trimester exposure; vasoconstriction may reduce uteroplacental blood flow, especially in third trimester. Avoid in first trimester if possible; use only if benefit outweighs risk.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
Desloratadine: Excreted into breast milk; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. Pseudoephedrine: Excreted into breast milk; estimated infant dose ~2-7% of maternal dose; may cause irritability, sleep disturbance. M/P ratio: not reported for desloratadine; pseudoephedrine M/P ~3.0. Manufacturer recommends caution due to pseudoephedrine's effects.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
No specific dose adjustments required for desloratadine; pregnancy may increase volume of distribution but no clinical studies. Pseudoephedrine: Pregnancy may reduce clearance; no formal dose adjustment but use lowest effective dose and shortest duration. Monitor for hypertension.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
CLARINEX-D 12 HOUR (desloratadine/pseudoephedrine) combines a non-sedating antihistamine with a sympathomimetic decongestant. Pseudoephedrine can cause hypertension, tachycardia, and urinary retention; avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Desloratadine is the active metabolite of loratadine; it is less sedating than first-generation antihistamines. The 12-hour formulation requires twice-daily dosing. Monitor for CNS stimulation and insomnia, especially in elderly or pediatric patients.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
Take one tablet every 12 hours with a full glass of water; do not crush or chew.,Do not exceed 2 tablets in 24 hours.,Avoid alcohol and other CNS depressants while taking this medication.,May cause dizziness or drowsiness; avoid driving until you know how the medication affects you.,Notify your doctor if you have high blood pressure, heart disease, thyroid problems, or difficulty urinating.,Discontinue use and seek medical attention if you experience chest pain, rapid heartbeat, or difficulty breathing.,Do not take with other decongestants or antihistamines without consulting a healthcare provider.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLARINEX-D 12 HOUR vs ACTAHIST, answered by our medical review team.
CLARINEX-D 12 HOUR is a Antihistamine/Decongestant Combination that works by Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.. ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLARINEX-D 12 HOUR and ACTAHIST depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLARINEX-D 12 HOUR is: 1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.. The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLARINEX-D 12 HOUR and ACTAHIST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLARINEX-D 12 HOUR is classified as Category C. Clarinox-D 12 Hour (desloratadine/pseudoephedrine) is classified as FDA Pregnancy Category C. Desloratadine: No adequate studies in pregnant women; animal studies show no teratogen. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.